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One of the major breakthroughs in Alzheimer’s disease (AD)
clinical research over the past two decades has been the vali-
dation of diagnostic biomarkers able to demonstrate the pres-
ence of pathological mechanisms of AD and to predict further
cognitive decline and dementia onset inmild cognitive impair-
ment (MCI) patients by identifying the prodromal stage of AD
[1, 2]. Among AD biomarkers, two main categories exist: (1)
amyloidosis biomarkers, able to identify a molecular feature
typical of AD: these include cerebrospinal fluid (CSF)
amyloid-β42 reduction and PET imaging using radiotracers
selectively binding to the fibrillar aggregates of amyloid-β
plaques; (2) neurodegeneration biomarkers reflecting neuro-
nal injury, such as the increase of tau and phosphorylated-tau
levels in the CSF, regional atrophy as measured by MRI and
demonstration of synaptic dysfunction/degeneration bymeans
of 18F-fluorodeoxyglucose (FDG) PET. Neurodegeneration
biomarkers are useful tools for further differential diagnosis
among amyloid positive and amyloid negative forms of de-
mentia, and also a prognostic tool in the MCI population.
In this framework, different sets of criteria for diagnosis of
AD at the stage of MCI have been proposed: the International
Working Group (IWG)-1 [1, 3] and IWG-2 [4], and National
Institute of Ageing Alzheimer Association (NIA-AA) criteria
[2]. These criteria differ with respect to the definition of the
biomarker abnormality needed to identify MCI at higher risk
to convert to AD. The IWG2 criteria have been developed
mainly for a research setting and propose to support clinical
suspicion of AD only by means of amyloidosis biomarkers
(defined as diagnostic biomarkers) [4]. By contrast, the NIA-
AA criteria were designed for both clinical and research pur-
poses and use the term ‘MCI due to AD^ for patients with
cognitive impairment in any cognitive domain and abnormal
amyloid markers or neuronal injury markers. In this frame,
NIA-AA criteria relate the number of abnormal biomarkers
to the likelihood that MCI is due to AD [2]. Although a pro-
spective comparison between these two different approaches
(IWG2 and NIA-AA) is still lacking, the validity of this NIA-
AA model has been confirmed by a large retrospective multi-
center study showing that, in the clinical setting, the combined
use of both amyloid and neuronal injury markers offers the
most accurate prognosis in MCI patients [5]. Similarly, in a
recent survey, neurologists working in European Alzheimer’s
Disease Consortium Centres agreed that only a combination
of amyloidosis and neuronal injury biomarkers is a strong
indicator of an underlying AD [6].
The use of AD biomarkers in routine clinical practice
should take into account not only the diagnostic performances
of a test but also cost-effectiveness estimates [7].
In this respect, the possibility of acquiring information
about amyloidosis and neurodegeneration with a single
biomarker/procedure offered by CSF measures is a clear ad-
vantage. However, standardization of CSF biomarkers is still
challenging (from handling of samples to identifying and
interpreting cut-offs) and international collaborative efforts
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are still ongoing to reduce the sources of their analytical var-
iability and standardization [8].
A novel modality of amyloid PET data acquisition might
also be able to evaluate both brain amyloidosis and neurode-
generation at the same time, namely the dual-phase amyloid
PET scanning described and adopted in the paper by Lin et al.
published in the present issue of the European Journal of
Nuclear Medicine and Molecular Imaging [9].
Dual-phase amyloid PET refers to the acquisition of a short
(usually 5 min) image immediately after injection, mirroring
perfusion imaging, followed by an interval of variable length,
depending on the kinetic properties of the specific tracer, and
by the late Bstandard^ acquisition at equilibrium to assess the
specific binding to amyloid plaques.
The concept of dual-phase scanning is not new; it has been
tested both with 11C-PIB and with 18F-Florbetapir and is
mainly linked to the fact that amyloid tracers have high
lipophilicity, which makes them good perfusion surrogates
[10, 11].
The data available so far show that early phase images have
strong similarities with FDG PET images in AD and
frontotemporal lobar degeneration [10, 12–14], can distin-
guish MCI from healthy controls [15], and recent evidence
suggests a potential diagnostic advantage also in patients with
cerebral amyloid angiopathy [16].
The perfusion imaging measured by the early acquisition,
is, according to the recent diagnostic criteria for AD, a
topographical/functional biomarker reflecting disease pro-
gression, in analogy with perfusion imaging measured by
SPECT or MRI techniques and brain glucose metabolism,
measured by FDG PET, while the late-phase amyloid PET
acquisition represents a pathophysiological marker, indicating
the presence of a disease-related molecular process.
The dual-phase approach, providing the possibility to in-
vestigate at once neuronal injury and molecular pathology, has
obvious advantages, as compared with two separate scans.
First, the radiation dose would be reduced at least by half,
as compared with a standard assessment with serial FDG and
amyloid PET.
Second, in a time in which economic hardship heavily
impacts clinical setup, the accurate evaluation of the cost-
effectiveness for diagnostic procedures is becoming of
vital importance in the diagnostic work-up [17].
Preliminary studies have shown that the use of biomarkers
might be cost-effective, but larger validation studies are
still required [18–20]. In this respect, dual-phase amyloid
PET allows to obtain pooled clinical information with
substantial sparing of direct medical costs as scanning
time and radiopharmaceutical expenses. In fact, this ap-
proach would be economically challenging for routine
clinical use, reducing the total cost by 1000 Euros,
avoiding additional FDG or other functional evaluations.
Furthermore, this Bone-stop-shop^ approach would reduce
non-medical costs as transportation fees and losses of
productivity due to sick leave.
The proposed methodology minimizes not only radiation
exposure but also patient and caregivers burden, avoiding for
patients to undergo a second examination with the associated
stress. Moreover, theinvestigation of multiple biomarkers at
once will reduce the time necessary to come to an early and
accurate diagnosis, accelerating case management, treatment
initiation, and ultimately increasing the efficacy of
theavailable therapies.
There are three main open issues to be addressed before
translating this approach into daily clinical practice. The first
regards the validation of the scanning and assessment methods
to be used for single-subject analysis of the early phase amy-
loid PET. All studies on this topic have so far shown that at the
group level, the distribution of perfusion, as measured by the
early phase of amyloid PET, is comparable (with some region-
al differences) to the distribution of metabolism shown by
FDG PET. However, none of these studies has assessed the
sensitivity and the reproducibility of this measure in individ-
ual cases.
The second concerns the sensitivity of this tool for a spe-
cific population, namely MCI subjects, to predict clinical pro-
gression. Indeed, we know that while amyloid negativity has
an excellent negative predictive value for conversion [21, 22],
among amyloid-positiveMCI subjects, the interval to progres-
sion can be variable, and functionalmeasures can predict more
accurately the time to conversion [23, 24]. Although the value
of FDG PET in this setting is well established, perfusion mea-
sures should be validated for this specific and highly interest-
ing indication [25–28].
A third issue, strongly linked with the previous ones, is the
need for a deeper investigation of the differences, and not only
the analogies, between perfusion surrogates, such as measured
by early phase PET scanning, and glucose metabolism
imaging in degenerative disorders. The interrelationship
between perfusion and metabolism might change along with
the disease progression and might be different in the early
disease stage, when changes are subtle and due to a
combinat ion of loca l neuronal dysfunc t ion and
disconnection mechanisms [29]. This aspect concerns not
only early phase amyloid scanning but also other measures
of perfusion, which are increasingly investigated in this
field, such as arterial-spin-labeling, as measured by MRI.
Perfusion and metabolism are indeed strongly coupled in the
brain, and a large body of literature has evaluated perfusion
changes in dementia and degenerative disorders, mainly by
perfusion SPECT, showing patterns of hypoactivity similar
to the patterns classically described for FDG PET. It is also
known that perfusion SPECT has lower sensitivity and
specificity, and this has been mainly explained by the
difference in spatial resolution between the two methods
[30]. However, detailed comparative analysis in the same
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individuals is still limited, and some recent data show that a
mismatch can be observed in various regions [12, 31].
In conclusion, the assessment of functional (e.g., perfusion)
changes is a validated and well-established biomarker for ear-
ly and differential diagnosis and prognostic evaluation in pa-
tients withMCI or dementia. The possibility of combining this
information to each amyloid PETscan at no additional costs is
very promising, and deserves larger testing in the nuclear
medicine community.
References
1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau
P, Cummings J, et al. Research criteria for the diagnosis of
Alzheimer’s disease: revising the NINCDS-ADRDA criteria.
Lancet Neurol. 2007;6(8):734–46. doi:10.1016/S1474-4422(07)
70178-3.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox
NC, et al. The diagnosis of mild cognitive impairment due to
Alzheimer’s disease: recommendations from the National Institute
on Aging-Alzheimer’s association workgroups on diagnostic
guidelines for Alzheimer’s disease. Alzheimers Dement.
2011;7(3):270–9. doi:10.1016/j.jalz.2011.03.008.
3. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST,
Barberger-Gateau P, et al. Revising the definition of Alzheimer’s
disease: a new lexicon. Lancet Neurol. 2010;9(11):1118–27. doi:
10.1016/S1474-4422(10)70223-4.
4. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL,
Blennow K, et al. Advancing research diagnostic criteria for
Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol.
2014;13(6):614–29. doi:10.1016/S1474-4422(14)70090-0.
5. Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W,
et al. Prevalence and prognosis of Alzheimer’s disease at the mild
cognitive impairment stage. Brain. 2015;138(Pt 5):1327–38. doi:
10.1093/brain/awv029.
6. Bocchetta M, Galluzzi S, Kehoe PG, Aguera E, Bernabei R,
Bullock R, et al. The use of biomarkers for the etiologic diagnosis
of MCI in Europe: an EADC survey. Alzheimers Dement.
2015;11(2):195–206 e1. doi:10.1016/j.jalz.2014.06.006.
7. Teipel S, Drzezga A, Grothe MJ, Barthel H, Chetelat G, Schuff N,
et al. Multimodal imaging in Alzheimer’s disease: validity and use-
fulness for early detection. Lancet Neurol. 2015;14(10):1037–53.
doi:10.1016/S1474-4422(15)00093-9.
8. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N,
Oberoi P, et al. Global standardization measurement of cerebral
spinal fluid for Alzheimer’s disease: an update from the
Alzheimer’s Association Global Biomarkers Consortium.
Alzheimers Dement. 2013;9(2):137–40. doi:10.1016/j.jalz.2012.
11.003.
9. Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, et al.
Imaging characteristic of dual-phase F-florbetapir (AV-45/Amyvid)
PET for the concomitant detection of perfusion deficits and beta-
amyloid deposition in Alzheimer’s disease and mild cognitive im-
pairment. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/
s00259-016-3359-8.
10. Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al.
Correlation of early phase 18F-florbetapir (AV-45/Amyvid) PET
images to FDG images: preliminary studies. Eur J Nucl Med Mol
Imaging. 2012;39(4):613–20. doi:10.1007/s00259-011-2051-2.
11. Blomquist G, Engler H, Nordberg A, Ringheim A, Wall A,
Forsberg A, et al. Unidirectional influx and net accumulation of
PIB. Open Neuroimag J. 2008;2:114–25. doi:10.2174/
1874440000802010114.
12. Rodriguez-Vieitez E, Carter SF, Chiotis K, Saint-Aubert L, Leuzy
A, Scholl M, et al. Comparison of early phase 11C-deuterium-L-
deprenyl and 11C-PiB PET for assessing brain perfusion in
Alzheimer’s disease. J Nucl Med. 2016. doi:10.2967/jnumed.115.
168732.
13. Forsberg A, Engler H, Blomquist G, Langstrom B, Nordberg A.
The use of PIB-PET as a dual pathological and functional biomark-
er in AD. Biochim Biophys Acta. 2012;1822(3):380–5. doi:10.
1016/j.bbadis.2011.11.006.
14. Rostomian AH,Madison C, Rabinovici GD, JagustWJ. Early 11C-
PIB frames and 18F-FDG PET measures are comparable: a study
validated in a cohort of AD and FTLD patients. J Nucl Med.
2011;52(2):173–9. doi:10.2967/jnumed.110.082057.
15. Gietl AF, Warnock G, Riese F, Kalin AM, Saake A, Gruber E, et al.
Regional cerebral blood flow estimated by early PiB uptake is re-
duced in mild cognitive impairment and associated with age in an
amyloid-dependent manner. Neurobiol Aging. 2015;36(4):1619–
28. doi:10.1016/j.neurobiolaging.2014.12.036.
16. Farid K, Hong YT, Aigbirhio FI, Fryer TD, Menon DK, Warburton
EA, et al. Early phase 11C-PiB PET in amyloid angiopathy-related
symptomatic cerebral hemorrhage: potential diagnostic value?
PLoS One. 2015;10(10), e0139926. doi:10.1371/journal.pone.
0139926.
17. Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW,
et al. Health economic evaluation of treatments for Alzheimer’s
disease: impact of new diagnostic criteria. J Intern Med.
2014;275(3):304–16. doi:10.1111/joim.12167.
18. Valcarcel-Nazco C, Perestelo-Perez L, Molinuevo JL, Mar J,
Castilla I, Serrano-Aguilar P. Cost-effectiveness of the use of bio-
markers in cerebrospinal fluid for Alzheimer’s disease. J
Alzheimers Dis. 2014;42(3):777–88. doi:10.3233/JAD-132216.
19. Moulin-Romsee G, Maes A, Silverman D, Mortelmans L, Van
Laere K. Cost-effectiveness of 18F-fluorodeoxyglucose positron
emission tomography in the assessment of early dementia from a
Belgian and European perspective. Eur J Neurol. 2005;12(4):254–
63. doi:10.1111/j.1468-1331.2004.00940.x.
20. Hornberger J, Michalopoulos S, Dai M, Andrade P, Dilla T,
Happich M. Cost-effectiveness of florbetapir-PET in Alzheimer’s
disease: a Spanish societal perspective. J Ment Health Policy Econ.
2015;18(2):63–73.
21. Lim HK, Nebes R, Snitz B, Cohen A, Mathis C, Price J, et al.
Regional amyloid burden and intrinsic connectivity networks in
cognitively normal elderly subjects. Brain. 2014;137(Pt 12):3327–
38. doi:10.1093/brain/awu271.
22. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ,
Vandenberghe R, et al. A European multicentre PET study of fi-
brillar amyloid in Alzheimer’s disease. Eur J Nucl Med Mol
Imaging. 2013;40(1):104–14. doi:10.1007/s00259-012-2237-2.
23. Prestia A, Caroli A, Wade SK, van der Flier WM, Ossenkoppele R,
Van Berckel B, et al. Prediction of AD dementia by biomarkers
following the NIA-AA and IWG diagnostic criteria inMCI patients
from three European memory clinics. Alzheimers Dement.
2015;11(10):1191–201. doi:10.1016/j.jalz.2014.12.001.
24. Zhang S, Han D, Tan X, Feng J, Guo Y, Ding Y. Diagnostic accu-
racy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term
conversion to Alzheimer’s disease in subjects with mild cognitive
impairment. Int J Clin Pract. 2012;66(2):185–98. doi:10.1111/j.
1742-1241.2011.02845.x.
25. Garibotto V, Herholz K, BoccardiM, Picco A,VarroneA,Nordberg
A et al. Maturity of FDG-PET as a biomarker for Alzheimer’s
disease in the context of a structured 5–phase development frame-
work. Neurobiol Aging (in press).
26. Pagani M, De Carli F, Morbelli S, Oberg J, Chincarini A, Frisoni
GB, et al. Volume of interest-based [18F]fluorodeoxyglucose PET
1302 Eur J Nucl Med Mol Imaging (2016) 43:1300–1303
discriminates MCI converting to Alzheimer’s disease from healthy
controls. A European Alzheimer’s Disease Consortium (EADC)
study. Neuroimage Clin. 2015;7:34–42. doi:10.1016/j.nicl.2014.
11.007.
27. Morbelli S, Garibotto V, Van De Giessen E, Arbizu J, Chetelat G,
Drezgza A, et al. A Cochrane review on brain [(1)(8)F]FDG PET in
dementia: limitations and future perspectives. Eur J Nucl Med Mol
Imaging. 2015;42(10):1487–91. doi:10.1007/s00259-015-3098-2.
28. Cerami C, Della Rosa PA, Magnani G, Santangelo R, Marcone A,
Cappa SF, et al. Brain metabolic maps in mild cognitive impairment
predict heterogeneity of progression to dementia. Neuroimage Clin.
2015;7:187–94. doi:10.1016/j.nicl.2014.12.004.
29. Villain N, Desgranges B, Viader F, de la Sayette V, Mezenge F,
Landeau B, et al. Relationships between hippocampal atrophy,
white matter disruption, and gray matter hypometabolism in
Alzheimer’s disease. J Neurosci. 2008;28(24):6174–81. doi:10.
1523/JNEUROSCI.1392-08.2008.
30. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurode-
generative dementias: comparison with perfusion SPECT and with
clinical evaluations lacking nuclear imaging. J Nucl Med.
2004;45(4):594–607.
31. Verclytte S, Lopes R, Lenfant P, Rollin A, Semah F, Leclerc X, et al.
Cerebral hypoperfusion and hypometabolism detected by arterial
spin labeling MRI and FDG-PET in early onset Alzheimer’s dis-
ease. J Neuroimaging. 2016;26(2):207–12. doi:10.1111/jon.12264.
Eur J Nucl Med Mol Imaging (2016) 43:1300–1303 1303
